scholarly journals Risk of Hepatitis B and Hepatitis C Among Whole Blood Transfused Chronic Hemodialysed Chronic Kidney Disease (CKD) Patients

2019 ◽  
Vol 30 (2) ◽  
pp. 78-82
Author(s):  
Md Abdul Quader ◽  
Khan Anisul Islam ◽  
Tashmim Farhana Dipta ◽  
Md Ashadul Islam
Keyword(s):  
Hepatitis C ◽  
Blood Transfusion ◽  
Hepatitis B ◽  
Hemodialysis Patients ◽  
Maintenance Hemodialysis ◽  
Control Group ◽  
Transmitted Infection ◽  
Transfusion Transmitted Infection ◽  
Healthy Donors ◽  
Significant Difference

Background: Patients with chronic renal failure on maintenance hemodialysis (MHD) have high risks of viral infections and the prevalence of transfusion transmissible viral infection is common among them. The aim of our study was to detect hepatitis B and hepatitis C virus in hemodialysis patients and healthy donors and to explore if there was a relationship between duration of hemodialysis and hepatitis B and hepatitis C in our patients. Methodology: A cross sectional study was conducted in a private hemodialysis clinic in Dhaka city with end stage renal disease on maintenance hemodialysis and an age matched healthy donors as comparable group from July 2015 to June 2016. Serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), HBsAg and anti HCV were determined along with duration and units of blood transfusion needed by them. Results: Our study showed the mean age of 126 MHD patients were 42.2±11.7 years along with 132 healthy donors as control group had mean age 39.2±9.7 years. Among the hemodialysis patients 34 (26.98%) showed transfusion transmitted infection positivity and in control group 11 (8.33%) showed transfusion transmitted infection positivity with the difference between two study group showed statistical significance (p<o.oo1). History of blood transfusion showed the significant predictor of occurrence of TTV infection in hemodialysis patients (p<0.01). Duration of hemodialysis and seropositivity of TTI was not significant (p>0.05). The number of units of blood transfusion and the TTI positivity also showed no significant difference (p>0.05) with HBsAg (17.46%) and anti HCV (9.52%). Conclusions: The prevalence of TTI in hemodialysis patients is significantly higher than that in healthy individuals. So, the regular screening of HBV and HCV among patients and healthy donors are strictly provided to monitor the communicable disease. Bangladesh J Medicine July 2019; 30(2) : 78-82

scholarly journals Decreasing Prevalence of Transfusion Transmitted Infection in Indian Scenario

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Tulika Chandra ◽  
S. Nishat Fatima Rizvi ◽  
Devisha Agarwal
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Transmitted Disease ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
Transfusion Transmitted Infection ◽  
Screening Procedures

Transfusion transmitted infections are major problem associated with blood transfusion. Accurate estimates of risk of TTIs are essential for monitoring the safety of blood supply and evaluating the efficacy of currently employed screening procedures. The present study was carried out to assess the percentage of voluntary donors and replacement donors and to find out prevalence and changing trends of various TTIs blood donors in recent years. A study was carried out on blood units of voluntary and replacement donors which were collected from January 2008 to December 2012. On screening of 180,371 replacement units, seropositivity of transfusion transmitted disease in replacement donors was 0.15% in HIV, 1.67% in hepatitis B surface antigen, 0.49% in hepatitis C virus, 0.01% in VDRL, and 0.009% in malaria. Of 11,977 voluntary units, seropositivity of transfusion transmitted disease in voluntary donors was 0.08% in HIV, 0.24% in hepatitis B surface antigen, 0.001% in hepatitis C virus, 0.008% in VDRL (sexually transmitted disease), and 0.01% in malaria. From results it has been concluded that prevalence of transfusion transmitted infection (HIV, HBV, HCV, VDRL, and malaria) was more in replacement donors in comparison to voluntary donors. Extensive donor selection and screening procedures will help in improving the blood safety.

scholarly journals Influence of hemoglobin level and dose of administered recombinant human beta erythropoietin on survival of hemodialysis patients

2011 ◽  
Vol 68 (9) ◽  
pp. 749-755
Author(s):  
Violeta Knezevic ◽  
Aleksandra Milosevic ◽  
Slavenka Vodopivec ◽  
Dusan Bozic ◽  
Ivana Budosan ◽  
...  
Keyword(s):  
Function Analysis ◽  
Underlying Disease ◽  
Hemodialysis Patients ◽  
Hemoglobin Level ◽  
Maintenance Hemodialysis ◽  
Control Group ◽  
Dialysis Duration ◽  
Significant Difference ◽  
The Difference ◽  
Stage Renal Disease

Background/Aim. In patients with end-stage renal disease, treatment with erythropoietin lowers cardiovascular morbidity, improves quality of life and patient survival. The aim of this study was to determine the difference in survival of hemodialysis patients treated with recombinant human beta erythropoietin and patients without this treatment, and to determine the influence of hemoglobin level and erythropoietin dose on the survival of these patients. Method. The study included 291 patients undergoing maintenance hemodialysis, 122 were on erythropoietin therapy, 169 patients formed control group. The study was performed at the Clinic for Nephrology and Clinical Immunology, Clinical Center of Vojvodina, during a 69-month period. We analyzed basic demographic parameters, dialysis duration, underlying disease, comorbidities, death causes, bloodwork parameters and erythropoietin dosage. Descriptive statistics, Anova, Manova, discriminant function analysis, Cox regressional model and Kaplan Meier survival curves were used as statistical methods. Results. Average age and dialysis duration in the experimental group were 47.88 ? 13.32 years, and 45.76 ? 46.73 months, respectively and in the control group 58.73 ? 12.67 years and 62.80 ? 55.23 months, respectively. Average level of hemoglobin and hematocrit in the group in which erythropoietin had been administered was 11.40 ? 8.39 g/dL and 0.35 ? 0.04/L, while the control group these values were 8.52 ? 7.73 g/dL and 0.26 ? 0.04/L, respectively. Average monthly dosage of erythropoietin was 21 587 ? 10 183.36 IJ/month. Significant difference in survival was determined (p < 0,05) between the stated patient groups. A significant difference (p < 0,05) was found in survival of the patients in which erythropoietin was administered regarding hemoglobin level (< 100 g/L/100-110 g/L/110-120 g/L/ > 120 g/L), as well as in regard of erythropoietin dose applied (< 20 000 IJ/20 000-40 000 IJ/ > 40 000 IJ/month). Conclusion. Best survival was noted in patients with hemoglobin > 120 g/L and erythropoietin dose < 20 000 IJ/month.

scholarly journals Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia

2017 ◽  
Vol 7 (3) ◽  
pp. 188-197 ◽  
Author(s):  
Takashi Maruyama ◽  
Terumi Higuchi ◽  
Toshio Yamazaki ◽  
Erina Okawa ◽  
Hideyuki Ando ◽  
...  
Keyword(s):  
Hemodialysis Patients ◽  
Renal Anemia ◽  
Maintenance Hemodialysis ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Human Erythropoietin ◽  
Significant Difference ◽  
Group 2 ◽  
To Receive ◽  
Esa Therapy

Aims: The aim of this study was to evaluate the efficacy of levocarnitine injection for renal anemia in hemodialysis patients. Methods: In this randomized controlled clinical trial, we randomly assigned patients on maintenance hemodialysis at our hospital to receive levocarnitine injections (n = 30) or no injection (n = 30) and monitored the patients during 12 months of treatment. In the treatment group, patients received an injection of levocarnitine 1,000 mg 3 times weekly after hemodialysis sessions. All patients received recombinant human erythropoietin as an erythropoiesis-stimulating agent (ESA). Response to ESA therapy was determined by calculating the erythropoietin responsiveness index (ERI; ESA dose·kg-1·g-1· dL-1·week-1). Results: (1) The target levels of hemoglobin and hematocrit were maintained during the study period in both the levocarnitine group and the control group. (2) The dose of ESAs required to maintain these levels decreased gradually in the levocarnitine group and was significantly lower at 6 and 12 months than at study initiation. Furthermore, the dose of ESAs was significantly lower than that in the control group at 12 months. (3) The ERI showed a significant decrease at 6 and 12 months in the levocarnitine group, with a significant difference between the 2 groups at 12 months. Conclusion: Our results suggest that levocarnitine administration can reduce the dose of ESAs required in patients with renal anemia on hemodialysis and improve the response to ESA therapy.

scholarly journals Seroprevalence of Hepatitis B, Hepatitis C and Human Immunodeficiency Virus Among Multitransfused Thalassaemic Children in Dhaka, Bangladesh

2014 ◽  
Vol 37 (3) ◽  
pp. 146-153 ◽  
Author(s):  
AKM Rezaul Karim ◽  
Afiqul Islam ◽  
Choudhury Yakub Jamal ◽  
Abdul Matin ◽  
Md Monir Hossain ◽  
...  
Keyword(s):  
Risk Factors ◽  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Transmitted Infection ◽  
Transfusion Transmitted Infection ◽  
B Virus ◽  
Immunodeficiency Virus

Background: Thalassaemia is a congenital hemolytic disease caused by defective globin chain synthesis of haemoglobin and largely treated by repeated blood transfusions. Transfusion-transmitted infections still make a great challenge in the management of patients with thalassaemia major. The most important worldwide transfusion transmitted infections (TTI) are hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Despite concern about a possible increase in the incidence of these infections there are no recent data about the prevalence of HBV, HCV and HIV from Bangladesh. Objectives: To evaluate the prevalence of hepatitis B, hepatitis C and human immunodeficiency virus in multi-transfused thalassaemia patients (MTP), to identify the possible risk factors and to evaluate the effect of compulsory screening of blood to prevent these infections. Methodology: This cross-sectional study was conducted during 2011 to 2012 on 100 consecutive multi-transfused thalassaemic patients who were interviewed using a structured questionnaire and tested for serological markers of hepatitis B virus (HBsAg), hepatitis C virus (Anti-HCV) and human immunodeficiency virus (Anti-HIV 1+2). Results: The overall prevalence of HCV, HBV, HIV and co-infection among (MTP) were 31%, 3%, 0% and 1%, respectively. Children who developed infection had a higher incidence of receiving transfusion from professional donors or unknown donors than the non-infected ones. Infected children had a higher frequency of receiving transfusions without screening and receiving more number of transfusions than their counterpart. Other non-transfusion related (NTR) risk factors such as surgical operation, dental procedures, needle stick injury were significantly higher in patients who acquired transfusion transmitted infections (TTI). Conclusions: HCV infection was the most prevalent transfusion transmitted infection (TTI) among multi-transfused thalassaemia patients (MTP) and remains a major health problem for these patients. Children who received transfusion from professional donors and received unscreened blood had more chance of getting infection with transfusion transmitted infection. DOI: http://dx.doi.org/10.3329/bjch.v37i3.18618 Bangladesh J Child Health 2013; Vol.37(3): 146-153

scholarly journals Prevalence and Risk Factors Associated with Hepatitis B and Hepatitis C Infections among Patients Undergoing Hemodialysis: A Single-Centre Study in Somalia

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Mohamed Osman Omar Jeele ◽  
Rukia Omar Barei Addow ◽  
Faduma Nur Adan ◽  
Liban Hassan Jimale
Keyword(s):  
Risk Factors ◽  
Hepatitis C ◽  
Blood Transfusion ◽  
Hepatitis B ◽  
Hemodialysis Patients ◽  
Cross Sectional ◽  
B Virus ◽  
Single Centre Study ◽  
History Of ◽  
The Mean

Introduction. Hemodialysis patients have the highest risk for developing hepatitis B virus (HBV) and hepatitis C virus (HCV) than the general population. There is no study available for HBV and HCV in this population in Somalia. The main objective of this study is to determine the prevalence and risk factors of HBV and HCV infections among hemodialysis patients in Somalia. Methods. A cross-sectional assessment of hemodialysis patients from January 2021 to June 2021 was used in this study. 220 patients were included in this study. Age, sex, duration of hemodialysis, number of hemodialysis sessions per week, history of blood transfusion, HbsAg, and anti-HCV antibodies were examined. Results. Out of the 220 patients, males were predominant (113 (51.4%)). The mean age of the participants was 52.70. The prevalence of HBV was 7.3% (16 respondents), while the prevalence of HCV was 3.2% (7 respondents). 1 respondent (0.5%) had both HBV and HCV. There is a positive correlation between the duration of hemodialysis and the prevalence of HBV and HCV (r(218) = 0.298, p value <0.001), blood transfusion and prevalence of HBV and HCV (r(218) = 0.347, p value <0.001), and the number of hemodialysis sessions per week and prevalence of HBV and HCV (r(218) = 0.402, p value <0.001). The regression model of the combined predictors of history of blood transfusion, duration of hemodialysis, and number of dialysis sessions per week is R2 = 0.25, which indicates a 25% variance in the prevalence of HBV and HCV with a significance of F (3,216) = 23.67, p < 0 .001 . Conclusions. The prevalence of HBV and HCV among hemodialysis patients in this study was 7.3% and 3.2%, respectively. 0.5% of the respondents had both HBV and HCV. History of blood transfusion, duration of hemodialysis, and number of hemodialysis sessions per week appear to have a strong correlation with the prevalence of HBV and HCV.

scholarly journals Seroprevalence of Hepatitis B and Hepatitis C in end-stage renal disease patients on maintenance hemodialysis: a single-center study from Bangladesh

2019 ◽  
Vol 6 (4) ◽  
pp. 1317
Author(s):  
S. M. Rahid Sarwar ◽  
A. K. M Mijanur Rahman ◽  
S. M. Mijanur Rahman ◽  
Shahjada Selim ◽  
A. B. M. Kamrul Hasan
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Blood Transfusion ◽  
Hepatitis B ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Military Hospital ◽  
Maintenance Hemodialysis ◽  
Stage Renal Disease ◽  
End Stage

Background: Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections are important causes of morbidity and mortality in hemodialysis (HD) patients. The aim of this study was to estimate the seroprevalence of HBV and HCV among end-stage renal disease (ESRD) patients on maintenance HD.Methods: This cross-sectional study was conducted in the hemodialysis unit of a military hospital of Bangladesh from October 2013 to March 2014 and included 141 maintenance HD patients. All patients were assessed by HBsAg and anti-HCV antibodies in addition to routine liver function tests.Results: The age range of the study subjects were 18-70 years, and the majority (85.11%) were male. Among them 22 (15.60%) were positive for anti HCV, 5(3.5%) were positive for HBsAg, and 3 patients (2.13%) were positive for both HBsAg and anti-HCV. The duration of hemodialysis was higher in anti-HCV positive patients (49±24 vs. 25±10 months, p <0.05) than anti-HCV negative ones. Anti-HCV positive patients in this study received a higher number of blood transfusion (units) than anti-HCV negative patients (7.5±4.3 vs. 2.8±1.7 units, p <0.05). HBsAg positive patients also received a higher number of blood transfusion (units) than HBsAg negative patients (8.2±3.1 vs. 3.2±1.2 units, p <0.05).Conclusions: Hepatitis C virus was the major form of hepatitis in HD patients in this study. The duration of HD was higher in anti-HCV positive patients; the numbers of blood transfusion units were higher in patients positive for HCV and HBV than the negative ones.

scholarly journals Slower Progression of Arteriosclerosis in Maintenance Hemodialysis Patients with Menaquinone Supplementation: A Perspective Randomized, Placebo-Controlled Trial

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 78-78
Author(s):  
Jing Tan ◽  
Dan Xu ◽  
Anxiu Yang ◽  
Ruijun Ren
Keyword(s):  
Controlled Trial ◽  
Hemodialysis Patients ◽  
Vitamin K2 ◽  
Matrix Gla Protein ◽  
Maintenance Hemodialysis ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Clinical Trial Registry ◽  
Significant Difference ◽  
Maintenance Hemodialysis Patients

Abstract Objectives To investigate the effects of menaquinone on the progression of arteriosclerosis in maintenance hemodialysis patients, and to provide evidence for the clinical prevention strategy of cardiovascular diseases in maintenance hemodialysis patients. Methods In this perspective, randomized, placebo-controlled trial, 107 MHD patients were randomized into Vitamin K2 group (VK2, n = 60) that received vitamin K2(menaquinone) at a dose of 270 μg/d and control group (n = 47). The following measurements were taken at baseline and after 9 months: carotid pulse wave velocity (cPWV) was measured with ultrasound, dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP) was tested with enzyme-linked immunosorbent assay. Results After 9 months follow-up, 40 patients from the VK2 group and 38 patients from the control group were included in the analysis. The cPWV values of MHD patients was positively correlated with age (r = 0.293, P = 0.01) and hypertension complication (r = 0.495, P = 0.00). The baseline cPWV values of VK2 group and the control group did not show a significant difference (7.53 ± 1.47 vs. 7.28 ± 1.18 m/s, P = 0.24). After 9 months of intervention, cPWV values in VK2 group were lower than baseline, but not significant (7.60 ± 1.50 vs. 7.53 ± 1.47 m/s, P = 0.90). The cPWV values of the control group at 6 months were increased when compared with the baseline (7.21 ± 1.18 vs. 7.86 ± 1.14 m/s, P = 0.04) . The increment rate of cPWV(△cPWV) from VK2 group was significantly lower than the control group (1.32 ± 12.53% vs 10.40 ± 16.85%, P = 0.00) 3. Baseline dp-ucMGP level of VK2 group and the control group showed no significant difference (1802.30 ± 552.88 vs. 1698.15 ± 488.06 nmol/L, P = 0.67) . After 9 months, the dp-ucMGP level in VK2 group was significantly decreased (1802.30 ± 552.88 vs 1448.42 ± 456.08 nmol/L, P = 0.01) , and significantly lower than control group (1448.42 ± 456.08 vs 1705.42 ± 424.48 nmol/L, P = 0.03). Conclusions Menaquinone supplementation induced a marked reduction of inactive MGP, and may retard the progression of arteriosclerosis in maintenance hemodialysis patients. This trial was registered at the Chinese Clinical Trial Registry as ChiCTR1900028459. Funding Sources None.

scholarly journals The effect of paricalcitol on Hepatitis B immunization in hemodialysis patients

2020 ◽  
Vol 7 (7) ◽  
pp. 549-553
Author(s):  
Mustafa Demir ◽  
Gamze İçaçan ◽  
Burkay Yakar ◽  
Ayhan Doğukan
Keyword(s):  
Hepatitis B ◽  
Risk Groups ◽  
Treated Group ◽  
Maintenance Hemodialysis ◽  
Control Group ◽  
High Morbidity ◽  
Significant Difference ◽  
Group 2 ◽  
And Gender ◽  
Group 1

Objective: Hepatitis B virus (HBV) infection has high morbidity and mortality. Therefore vaccination for HBV is crucial, especially for risk groups. In this study, we aimed to determine the effect of paricalcitol on HBV immunization in maintenance hemodialysis (HD) patients. Methods: Forty-two maintenance HD patients enrolled in the study. Group 1 was the control group who didn't receive paricalcitol treatment (n:28, control group). Group 2 was the paricalcitol treatment group for secondary hyperparathyroidism (n:14, paricalcitol group). Anti-HBs titers were measured with a three-month interval for two times. Results: The mean age of the patients in Group 1 was 58.50(18-80) years, while of the patients in Group 2 was 46.50 (23-81) years. There was no statistically significant difference between the groups in terms of age and gender (p = 0.200, p = 0.508, respectively). Baseline anti-HBs titer in the control group was 190.32 IU/L (20.18-1000), and 187.89 IU/L (38.77-1000) in the paricalcitol treated group. After 3 months of follow-up, anti-HBs titers decreased to 114.72 IU/L (13.68-1000) from 190.32 IU/L (20.18-1000) in the control group and to the 175.27 IU/L (14.25-1000) from 187.89 IU/L (38.77-1000) in the paricalcitol group. The decrease in anti-HBs titers was significant in the control group, whereas it was not significant in the paricalcitol group (P = 0.001, 0.209, respectively). Conclusion: The protective effect of paricalcitol on hepatitis B seroconversion in HD patients was observed. We think that paricalcitol may be used as an adjuvant for hepatitis B seroconversion.

scholarly journals Seroprevalence of Hepatitis C, Hepatitis B, Cytomegalovirus, and Human Immunodeficiency Viruses in Multitransfused Thalassemic Children in Upper Egypt

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Ramadan A. Mahmoud ◽  
Abdel-Azeem M. El-Mazary ◽  
Ashraf Khodeary
Keyword(s):  
Hepatitis C ◽  
Blood Transfusion ◽  
Hepatitis B ◽  
Thalassemia Major ◽  
Upper Egypt ◽  
Egyptian Children ◽  
Hiv Type 1 ◽  
Anti Hiv

Background. Frequent blood transfusions in thalassemia major children expose them to the risk of transfusion-transmitted infections (TTIs). The aim of this study was to estimate the prevalence of hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), and cytomegalovirus (CMV) in thalassemic children attending the Pediatrics Departments of both Sohag and Minia Universities of Upper Egypt, during the period from May 2014 to May 2015.Methods. Serum samples were screened for hepatitis B surface antigen (HBsAg), anti-HCV, anti-CMV, and anti-HIV type 1 and type 2 using the Vitek Immunodiagnostic Assay System.Results. The frequencies of anti-HCV, HBsAg, anti-CMV, and anti-HIV type 1 and type 2 were found to be 37.11%, 4.12%, 4.12%, 0.00%, and 0.00%, respectively. Seropositivity for anti-HCV, HBsAg, and anti-CMV increased with increasing age of the patients, duration of the disease, serum ferritin level (ng/mL), and liver enzymes (U/L), while it was not significantly associated with gender, frequency of blood transfusion, or the status of splenectomy operation (P>0.05).Conclusion. The frequency of TTIs, especially HCV, is considerably high among Egyptian children with thalassemia major. It is therefore important to implement measures to improve blood transfusion screening, such as polymerase chain reaction, in order to reduce TTIs from blood donor units.

Sign in / Sign up

Export Citation Format

Share Document